Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study

Eur J Dermatol. 2022 Nov 1;32(6):800-802. doi: 10.1684/ejd.2022.4365.

Authors

Keiji Kosaka¹, Akihiko Uchiyama¹, Mai Ishikawa¹, Goichi Watanabe², Sei-Ichiro Motegi¹

Affiliations

¹ Department of Dermatology, Gunma University Graduate School of Medicine, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan.
² Department of Dermatology, Public Tomioka General Hospital, 2073-1 Tomioka, Tomioka, Gunma 370-2393, Japan.

PMID: 36856388
DOI: 10.1684/ejd.2022.4365

No abstract available

Publication types

Multicenter Study

MeSH terms

Dermatitis, Atopic* / drug therapy
East Asian People
Heterocyclic Compounds, 3-Ring* / therapeutic use
Humans
Retrospective Studies

Substances

Heterocyclic Compounds, 3-Ring
upadacitinib